Using CancerenD24 to help diagnose cancer early
Official title: Clinical Validation Of A Diagnostic Cancerend24 Screening As An Aid To The Clinician For The Diagnosis Of Cancer In Healthy Subjects Attending The ICPC
Run by Tel-Aviv Sourasky Medical Center · NCT06656728 · Data updated 2026-11-12
This study is testing a new blood test called CancerenD24 to see if it can help find cancer early in people aged 40 and older, even before they have any symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Tel-Aviv Sourasky Medical Center Government |
| Locations | 1 site (Tel Aviv) |
| Status | Recruiting |
| Started | September 3, 2024 |
| Main results expected | September 4, 2024 |
| Study ends | September 2027 |
| Registry record updated | October 24, 2024 |
| Trial ID | NCT06656728 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy individuals aged 40 and older who are willing to participate and provide informed consent.
✕Probably not a fit
Patients under 40 years of age, those with active cancer, or individuals with certain medical conditions such as inflammatory bowel disease will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the CancerenD24 index, which utilizes an algorithm based on the expression levels of CD24 and CD11b proteins in blood samples to assist in the early detection of cancer. The study will recruit 2000 participants aged 40 and older, who will undergo routine blood tests to measure these protein levels alongside clinical and laboratory characteristics. The goal is to determine if this method can effectively identify malignant diseases in healthy individuals before symptoms arise. The test is designed for routine clinical use and is not influenced by fasting or the time of day when samples are collected.
Why it matters
Potential benefit: If successful, this approach could significantly enhance early cancer detection, leading to better treatment outcomes for patients.
How similar studies have gone: Other studies have explored similar blood-based biomarkers for cancer detection, showing promising results, but the CancerenD24 approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Completion of all medical exams and questionnaires including cancer diagnoses, demographic data and other epidemiologic information 2. Willing and able to sign an informed consent 3. Age ≥40 years Exclusion Criteria: 1. Age \< 40 years 2. Pregnancy or breastfeeding 3. Any type of fever 4. Any cancer active at study entry or up to 5 years prior to study entry 5. Polyposis syndromes 6. Inflammatory bowel disease 7. Unwilling or unable to provide informed consent
Where it's running
-
Integrated Cancer Prevention Center at the Tel Aviv Sourasky Medical Center Ichilov
Tel Aviv, Israel Recruiting
Study contacts
- Study coordinator: Nadir Arber, Professor
- Email: nadira@tlvmc.gov.il
- Phone: +972 036973561
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Empowering patients to get lung cancer screening with support and navigation
This pilot study tests a patient navigation and education program to see if it helps adults who are eligible start and complete low-dose CT lung cancer screening.
-
Breast ultrasound screening for older women in community clinics
This study tests whether offering breast ultrasound to women aged 65–80 in local communities helps find breast cancers earlier than usual care.
-
Text reminders to boost colorectal cancer screening participation
A large group of people aged 50–69 in Vallès Occidental will be randomised to receive a reminder text message five weeks after an initial invitation, to see if it increases uptake of the FIT screening compared with the standard postal letter.
-
Menstrual cup for early detection of endometrial cancer in Lynch syndrome
This project will test whether using a menstrual cup can collect uterine lining samples that help detect early endometrial cancer in menstruating people who carry Lynch syndrome gene changes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.